The U.S. tariffs on China include a broad 10% levy on imported goods. China’s response was more targeted, with 15% tariffs on ...

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

Meanwhile, it doesn't seem coincidental that Illumina, which is the most significant genetic sequencing business in the world, has a large Chinese rival in biotech BGI Genomics. Ever feel like you ...

There were also mutations identified in ctDNA alone ... to undertake multiomics by enabling RNA and protein sequencing on Illumina platforms which is not possible with ctDNA.

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...

enabling analysis of large gene panels and cancer specific mutations. Illumina is the world’s largest provider of NGS systems and assays and has built an installed base of more than 23,000 sequencing ...

There were also mutations identified in ctDNA alone ... to undertake multiomics by enabling RNA and protein sequencing on Illumina platforms which is not possible with ctDNA.

NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform. Findings in lung cancer show that CTCs can provide additional biomarkers not found ...